WO2004033447A1 - Imidazole derivatives and their use as peripherally-selective inhibitors of dopamine-beta-hydroxylase - Google Patents
Imidazole derivatives and their use as peripherally-selective inhibitors of dopamine-beta-hydroxylase Download PDFInfo
- Publication number
- WO2004033447A1 WO2004033447A1 PCT/GB2003/004430 GB0304430W WO2004033447A1 WO 2004033447 A1 WO2004033447 A1 WO 2004033447A1 GB 0304430 W GB0304430 W GB 0304430W WO 2004033447 A1 WO2004033447 A1 WO 2004033447A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- dihydroimidazole
- thione hydrochloride
- aminoethyl
- group
- signifies
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic System
- C07F7/02—Silicon compounds
- C07F7/08—Compounds having one or more C—Si linkages
- C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
- C07F7/1804—Compounds having Si-O-C linkages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/695—Silicon compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/84—Sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
- C07D311/58—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Definitions
- This invention relates to peripherally-selective inhibitors of dopamine- ⁇ -hydroxylase and method of their preparation.
- D ⁇ H inhibitors are based on their capacity to inhibit the biosynthesis of noradrenaline, which is achieved via enzymatic hydroxylation of dopamine.
- Activation of neurohumoral systems, chiefly the sympathetic nervous system, is the principal clinical manifestation of congestive
- Prolonged 0 and excessive exposure of myocardium to noradrenaline may lead to down-regulation of cardiac ⁇ i-adrenoceptors, remodelling of the left ventricle, arrhytmias and necrosis, all of which can diminish the functional integrity of the heart.
- Congestive heart failure patients who have high plasma concentrations of noradrenaline also have the most unfavourable long-term prognosis (Cohn, J.N. et al., N. Engl. J. Med., 311 :819-823,
- nepicastat (RS-25560-197, IC 5 o 9nM) (Stanley, W.C., et al., Br. J Pharmacol., 121 : 1803-1809, 1997), which was developed to early clinical trials.
- BBB blood brain barrier
- D ⁇ H inhibitor with similar or even greater potency than nepicastat, but devoid of CNS effects (inability to cross the BBB) would provide a significant improvement over all D ⁇ H inhibitor compounds thusfar described in the prior art.
- Ri, R 2 and R 3 are the same or different and signify hydrogens, halogens, alkyl, alkylaryl, alkyloxy, hydroxy, nitro, amino, alkylcarbonylamino, alkylamino or dialkylamino group;
- R signifies hydrogen, alkyl or alkylaryl group;
- X signifies CH 2 , oxygen atom or sulphur atom;
- n is 1 , 2 or 3, with the proviso that when n is 1 , X is not CH 2 ; and the individual (R)- and (S)-enantiomers or mixtures of enantiomers; and the pharmaceutically acceptable salts thereof.
- alkyl (whether used on its own or used in combination with other moieties) means hydrocarbon chains, straight or branched, containing from one to six carbon atoms, optionally substituted by aryl, alkoxy, halogen, alkoxycarbonyl or hydroxycarbonyl groups;
- aryl (whether used on its own or used in combination with other moieties) means a phenyl or naphthyl group, optionally substituted by alkyloxy, halogen or nitro group;
- halogen means fluorine, chlorine, bromine or iodine.
- Another aspect of the present invention is a process for the preparation of compounds of formula I.
- Some compounds according to formula II where X signifies methylene (CH 2 ), oxygen or sulphur are known (Martinez, G.R. et al., US Patent 5,538,988, Jul. 23, 1996; Eriksson, M., PCT Int. Appl. WO 9959988A1 , 25 Nov 1999; Napoletano, M., PCT Int. Appl. WO 9608489A1 , 21 March 1996; Sarda, N. et al., Tetrahedron Lett., 17:271-272, 1976; Neirabeyeh, M.AI et al., Eur. J. Med.
- R 1 R 2 and R 3 are the same or different and signify hydrogens, halogens, alkyl, alkylaryl, alkyloxy, hydroxy, nitro, alkylcarbonylamino, alkylamino or dialkylamino group with a compound of formula III:
- n signifies 1 , 2 or 3; when n is 1 or 2, R 4 signifies hydrogen, alkyl or alkylaryl group; R 5 signifies a hydroxyl protecting group and Re signifies an amino protecting group; when n signifies 3, R 5 is defined as above but R and R 6 taken together represent a phthalimido group; and with a water soluble thiocyanate salt in an inert organic solvent and in the presence of an organic acid, wherein the water soluble thiocyanate salt is an alkali metal thiocyanate salt or a tetraalkylammonium thiocyanate salt.
- Suitable alkali metal thiocyanate salts include sodium, lithium and cesium thiocyanates, but potassium thiocyanate is preferred.
- the compound of formula III where n is 1 is known (Wolf, E. et al., Can. J. Chem., 75:942-948, 1997) and compounds of formula III where n is 2 or 3 are new compounds that can be prepared by those skilled in the art (see examples).
- the preferred hydroxyl protecting groups (R 5 ) include organosilyl compounds such as chosen from trialkysilyl, triphenylsilyl, phenyldialkylsilyl or alkyldiphenylsilyl group.
- TDMS tert-butyldimethylsilyl
- the preferred amino protecting groups (R 6 ) include carbamates such alkyl carbamates, in particular the t-butyl carbamate (Boc) group, and alkylaryl carbamates.
- the reaction may be run with a small excess of the compound of formula III and potassium thiocyanate (preferably 1.1-1.3 equivalents).
- the invention also provides compounds of formula II, where at least one of R-i, R 2 and R 3 is fluorine.
- the reaction can be run in a substantially inert solvent (preferably ethyl acetate) and at different temperatures (preferably at the solvent reflux temperature).
- Preferred organic acids include acetic acid.
- the intermediate of formula IV is then treated with a mineral acid in a suitable solvent to remove the Boc amino protecting group and provide the compounds of formula I (scheme 1).
- Preferred mineral acids include hydrochloric acid and preferred solvents include ethyl acetate.
- inert pharmaceutically acceptable carriers are admixed with the active compounds.
- the pharmaceutically acceptable carriers may be either solid or liquid. Solid form preparations include powders, tablets, dispersible granules and capsules.
- a solid carrier can be one or more substances which may also act as diluents, flavouring agents, solubilizers, lubricants, suspending agents, binders or tablet disintegrating agents; it may also be an encapsulating material.
- the pharmaceutical preparation is in unit dosage form, e.g. packaged preparation, the package containing discrete quantities of preparation such as packeted tablets, capsules and powders in vials or ampoules.
- the dosages may be varied depending on the requirement of the patient, the severity of the disease and the particular compound being employed. For convenience, the total daily dosage may be divided and administered in portions throughout the day. It is expected that once or twice per day administration will be most suitable. Determination of the proper dosage for a particular situation is within the skill of those in the medical art.
- D ⁇ H activity was evaluated by the ability to ⁇ -hydroxylate dopamine to noradrenaline as previously described (Kojima, K., Parvez, S. and Nagatsu T. 1993. Analysis of enzymes in catecholamine biosynthesis. In Methods in Neurotransmitter and Neuropeptide Research, pp. 349-380: Elsiever Science Publishers).
- SK-N-SH cells ATCC HTB-11
- a human neuroblastoma derived cell line were used as a source of human D ⁇ H.
- SK-N- SH cells cultured in 24 well plates were preincubated for 20 min in a reaction medium containing 200 mM sodium acetate, 30 mM -ethylmaleimide, 5 ⁇ M copper sulphate, 0.5 mg/ml catalase aqueous solution, 1 mM pargyline, 10 mM sodium fumarate and 20 mM ascorbic acid. Thereafter, cells were incubated for further 45 min in the reaction medium with added increasing concentrations of dopamine (0.5 to 100 mM). During preincubation and incubation, the cells were continuously shaken and maintained at 37°C. The reaction was terminated by the addition of 0.2 M perchloric acid.
- test compounds 0.3 to 10,000 nM were added to the preincubation and incubation solutions; the incubation was performed in the presence of a concentration (50 mM) of dopamine 2.5 times the corresponding K m value as determined in saturation experiments.
- mice or Wistar rats Male NMRI mice or Wistar rats were obtained from Harlan-lnterfauna (Spain) and were kept 10 and 5 per cage respectively, under controlled environmental conditions (12 h light/dark cycle and room temperature 22 ⁇ 1 °C). Food and tap water were allowed ad libitum and experimentation was performed during daylight hours.
- mice were administered with either test compounds at a given dose or vehicle (water) delivered orally via gavage.
- vehicle water
- the animals were sacrificed by decapitation and heart (left atrium and left ventricle) and brain (frontal and parietal cortex) were isolated, weighed and stored in a volume of 0.2 M perchloric acid for 12 h at 4 °C in the dark.
- Post incubation the resulting supematants were collected by centrifuge filtration of incubates (0.2 ⁇ M I 10 min / -5000 rpm, 4 °C). Supematants were stored frozen at -80 °C until analysis. Quantification of dopamine and noradrenaline in supematants was performed by high pressure liquid chromatography with electrochemical detection. Results
- nepicastat 1 (the reference compound) produced a concentration-dependent decrease in the li-hydroxylation of dopamine with IC 5 0 values in the low nM range against human D ⁇ H activity (see Table 2).
- Compound 4 was chosen for further in vivo studies, being the compound most closely related to nepicastat 1 in order to provide conclusive evidence that the structural modifications made to the molecule as part of the present invention are responsible for the surprisingly markedly improved biological properties observed.
- both 4 and 1 reduced noradrenaline levels in a dose- dependent manner in left ventricle.
- the maximal inhibitory effect was attained at a dose of 100 mg/kg.
- 4 failed to affect noradrenaline tissue levels in the brain parietal cortex, whereas 1 produced a dose- dependent decrease in noradrenaline levels in this area of the brain ( Figure 2).
- Figure 1 is a graph showing the time-dependent decrease of noradrenaline levels in the left ventricle of mice treated orally with 100 mg/kg of 4 or nepicastat 1. Symbols are means of 5 determinations per group; vertical lines indicate S.E.M.
- Figure 2 is two graphs showing noradrenaline levels in the mouse left ventricle and brain parietal cortex 9 h after oral administration of 4 or nepicastat 1. Symbols are means of 5 determinations per group; vertical lines indicate S.E.M.
- Figure 3 is four graphs showing noradrenaline levels in the rat heart (left atrium and left ventricle) and brain (frontal and parietal cortex) 9 h after the oral administration of 4 or nepicastat 1. Columns are means of 5 determinations per group; vertical lines indicated S.E.M.
- Some compounds of general formula I are very potent dopamine- ⁇ -hydroxylase inhibitors and have potentially valuable pharmaceutical properties in the treatment of some cardiovascular disorders, where a reduction in the enzymatic hydroxylation of dopamine to noradrenaline may be of therapeutic benefit, such as hypertension and chronic heart failure.
- a reduction in the enzymatic hydroxylation of dopamine to noradrenaline may be of therapeutic benefit, such as hypertension and chronic heart failure.
- CNS brain
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Epidemiology (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pyrane Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Description
Claims
Priority Applications (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020057006221A KR101155159B1 (en) | 2002-10-11 | 2003-10-10 | Imidazole derivatives and their use as peripherally-selective inhibitors of dopamine-beta-hydroxylase |
BRPI0315143A BRPI0315143B8 (en) | 2002-10-11 | 2003-10-10 | compound, pharmaceutical composition, and use of a compound |
MXPA05003847A MXPA05003847A (en) | 2002-10-11 | 2003-10-10 | Imidazole derivatives and their use as peripherally-selective inhibitors of dopamine-beta-hydroxylase. |
KR1020127005102A KR101350741B1 (en) | 2002-10-11 | 2003-10-10 | Imidazole derivatives and their use as peripherally-selective inhibitors of dopamine-beta-hydroxylase |
CA2501819A CA2501819C (en) | 2002-10-11 | 2003-10-10 | Imidazole derivative and their use as peripherally-selective inhibitors of dopa nine-beta-hydroxylase |
AU2003271945A AU2003271945B2 (en) | 2002-10-11 | 2003-10-10 | Imidazole derivatives and their use as peripherally-selective inhibitors of dopamine-beta-hydroxylase |
JP2004542666A JP4620464B2 (en) | 2002-10-11 | 2003-10-10 | Imidazole derivatives as peripherally selective inhibitors of dopamine-beta-hydroxylase and their use |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB0223719A GB2393958A (en) | 2002-10-11 | 2002-10-11 | Peripherally-selective imidazole inhibitors of dopamine-beta-hydroxylase |
GB0223719.6 | 2002-10-11 | ||
GB0224306.1 | 2002-10-18 | ||
GB0224306A GB2394223B (en) | 2002-10-11 | 2002-10-18 | Peripherally-selective inhibitors of dopamine-beta-hydroxylase and method of their preparation |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2004033447A1 true WO2004033447A1 (en) | 2004-04-22 |
Family
ID=32031889
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/GB2003/004430 WO2004033447A1 (en) | 2002-10-11 | 2003-10-10 | Imidazole derivatives and their use as peripherally-selective inhibitors of dopamine-beta-hydroxylase |
Country Status (13)
Country | Link |
---|---|
US (2) | US7125904B2 (en) |
EP (5) | EP1914233B8 (en) |
JP (1) | JP4620464B2 (en) |
KR (1) | KR101155159B1 (en) |
AU (1) | AU2003271945B2 (en) |
BR (1) | BRPI0315143B8 (en) |
CA (1) | CA2501819C (en) |
GB (2) | GB2432159B (en) |
MX (1) | MXPA05003847A (en) |
PL (1) | PL218537B1 (en) |
PT (1) | PT103029B (en) |
RU (1) | RU2332416C2 (en) |
WO (1) | WO2004033447A1 (en) |
Cited By (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007081232A1 (en) * | 2006-01-13 | 2007-07-19 | Bial- Portela & Ca, S.A. | Drug combinations |
WO2007139413A2 (en) | 2006-05-31 | 2007-12-06 | Bial - Portela & C.A., S.A. | Polymorphs of (r) -5- (2-aminoethyl) -1- (6, 8-difluorochroman-3-yl) -1,3- dihydroimidazole-thione hydrochloride |
WO2008085074A2 (en) * | 2007-01-12 | 2008-07-17 | Bial-Portela & Ca., S.A. | 1, 3-dihydroimidazoles for treating cardiovascular disorders |
WO2008094055A1 (en) * | 2007-02-01 | 2008-08-07 | Bial-Portela & Ca, S.A. | Process for the preparation of (r) -5- (2-aminoethyl) -1- (6, 8-difluorochroman-3-yl) -1, 3-dihydroimidazole-2-thione |
WO2008094056A1 (en) * | 2007-02-01 | 2008-08-07 | Bial - Portela & Ca, S.A. | Process for the preparation of (r) -5- (2-aminoethyl) -1- (6, 8 -di fluorochroman- s -yl ) -1, 3-dihydroimidazole-2-thione |
WO2008094054A3 (en) * | 2007-02-01 | 2008-09-18 | Portela & Ca Sa | 6, 8-dichlorchroman-3-yl-l, 3-dihydroimidazole-2-thione derivatives and their use for the treatment of cardiovascular disorders |
WO2008136695A1 (en) * | 2007-05-08 | 2008-11-13 | Portela & Ca, S.A. | 1, 3-dihydroimidazole- 2 -thione derivatives as inhibitors of dopamine-beta-hydroxylase |
WO2009072915A1 (en) | 2007-12-05 | 2009-06-11 | Bial - Portela & Ca., S.A. | New salts and crystal forms |
WO2009113891A1 (en) * | 2008-03-13 | 2009-09-17 | Bial - Portela & Ca., S.A. | Catalytic process for asymmetric hydrogenation |
WO2009136803A3 (en) * | 2008-05-06 | 2010-07-22 | Bial - Portela & Ca., S.A. | Catalytic process for asymmetric hydrogenation |
WO2013002660A2 (en) | 2011-06-29 | 2013-01-03 | BIAL - PORTELA & Cª, S.A. | Process |
US8546571B2 (en) | 2006-12-12 | 2013-10-01 | BIAL—Portela & C.A., S.A. | Catalytic hydrogenation of ene-carbamates |
WO2014077715A1 (en) * | 2012-11-14 | 2014-05-22 | BIAL - PORTELA & Cª, S.A. | 1,3-dihydroimidazole-2-thione derivatives for use in the treatment of pulmonary arterial hypertension and lung injury |
US8957222B2 (en) | 2008-03-19 | 2015-02-17 | Bial-Portela & Ca, S.A. | Process for preparing intermediates of peripherally-selective inhibitors of dopamine-β-hydroxylase involving catalytic asymmetric hydrogenation |
WO2018056855A1 (en) * | 2016-09-23 | 2018-03-29 | BIAL - PORTELA & Cª, S.A. | Dopamine-b-hydroxylase inhibitors |
WO2019112457A1 (en) | 2017-12-04 | 2019-06-13 | BIAL - PORTELA & Cª, S.A. | Dopamine-β-hydroxylase inhibitors |
US10329268B2 (en) | 2013-09-13 | 2019-06-25 | Bial-Portela & Ca, S.A. | Processes for preparing medicaments for the treatment of cardiovascular diseases and intermediates for use therein |
WO2020005087A1 (en) | 2018-06-25 | 2020-01-02 | Bial - Portela & Ca, S.A. | FORMULATIONS COMPRISING DOPAMINE-β-HYDROXYLASE INHIBITORS AND METHODS FOR THEIR PREPARATION |
US10821186B2 (en) | 2008-11-10 | 2020-11-03 | Arbutus Biopharma Corporation | Lipids and compositions for the delivery of therapeutics |
WO2020246903A1 (en) | 2019-06-05 | 2020-12-10 | BIAL - PORTELA & Cª, S.A. | Dopamine-β-hydroxylase inhibitors |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008115706A1 (en) * | 2007-03-16 | 2008-09-25 | Emory University | Methods and compositions for treatment of drug addiction |
GB0709695D0 (en) * | 2007-05-21 | 2007-06-27 | Portela & Ca Sa | Process |
TW200927740A (en) * | 2007-11-13 | 2009-07-01 | Bial Portela & Ca Sa | Process |
US8313984B2 (en) * | 2008-03-19 | 2012-11-20 | Ati Technologies Ulc | Die substrate with reinforcement structure |
JP5574480B2 (en) * | 2009-03-12 | 2014-08-20 | 国立大学法人高知大学 | Amino group-containing acetone derivative and carbon-carbon bond forming method using the same |
CN104698749B (en) * | 2010-01-25 | 2019-11-19 | 罗门哈斯电子材料有限公司 | Photoresist comprising nitrogenous compound |
JP6161538B2 (en) * | 2010-12-22 | 2017-07-12 | バイアル−ポルテラ アンド シーエー,エス.エー. | Crystal form and manufacturing method thereof |
EP3971178A1 (en) | 2012-03-07 | 2022-03-23 | The McLean Hospital Corporation | Aminoquinoline derivatives and uses thereof |
WO2020123699A1 (en) * | 2018-12-11 | 2020-06-18 | The Trustees Of Columbia University In The City Of New York | Compounds and compositions that cause mycn and/or cmyc degradation and methods of use thereof |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1995029165A2 (en) * | 1994-04-26 | 1995-11-02 | Syntex (U.S.A.) Inc. | Benzocycloalkylaz0lethione derivatives as dopamin beta-hydroxylase inhibitors |
Family Cites Families (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ATE63744T1 (en) | 1985-09-03 | 1991-06-15 | Ciba Geigy Ag | 3-AMINO-DIHYDRO-(1>-BENZOPYRANES AND BENZOTHIOPYRANES. |
EP0295401A3 (en) * | 1987-04-30 | 1990-03-21 | Wacker-Chemie Gmbh | Process for polymerizing polar compounds |
FR2619113B2 (en) | 1987-05-26 | 1991-06-28 | Exsymol Sa | NOVEL SILANOL CONDENSING PRODUCTS, THEIR PREPARATION AND APPLICATION |
US4868210A (en) * | 1988-03-30 | 1989-09-19 | Warner-Lambert Company | Antihyperlipidemic and antiatherosclerotic compounds and compositions |
US5013854A (en) | 1989-02-02 | 1991-05-07 | Eli Lilly And Company | Process for preparing acid halides |
SE8904361D0 (en) | 1989-12-22 | 1989-12-22 | Astra Ab | NEW CHROMAN AND THIOCHROMAN DERIVATIVES |
DK0510068T3 (en) * | 1990-01-11 | 1999-10-25 | Upjohn Co | New 6,7,8,9-tetrahydro-3H-benz (e) indole heterocycles with effect on the central nervous system |
IT1241988B (en) | 1990-06-15 | 1994-02-02 | Sigma Tau Ind Farmaceuti | 2- AMMINOTETRALINE-6, 7-ACTIVE SUBSTITUTES AS IMMUNOMODULANTS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM |
DD297249A5 (en) | 1990-08-07 | 1992-01-02 | Veb Mineralwollewerk Flechtingen Bereich F/E Mineralwolle,De | METHOD FOR AUTOMATIC MONITORING OF THE BONED GRADE ON MATERIAL RAILS |
US5438150A (en) * | 1994-04-26 | 1995-08-01 | Syntex (U.S.A.) Inc. | Process for making 1-benzocycloalkyl-1,3-dihydroimidazole-2-thione derivatives |
US5538988A (en) * | 1994-04-26 | 1996-07-23 | Martinez; Gregory R. | Benzocycloalkylazolethione derivatives |
GB2290790A (en) | 1994-06-30 | 1996-01-10 | Merck & Co Inc | Asymmetric synthesis of 6-substituted 2-amino-1,2,3,4-tetrahydronaphthalenes |
IT1271009B (en) | 1994-09-13 | 1997-05-26 | Zambon Spa | BENZOPYRANE AND BENZOTHIOPYRANE DERIVATIVES ACTIVE IN THE CARDIOVASCULAR SYSTEM |
JPH08259572A (en) * | 1995-01-24 | 1996-10-08 | Toyama Chem Co Ltd | New cephalosporin derivative or its salt |
IT1278045B1 (en) | 1995-03-09 | 1997-11-17 | Sigma Tau Ind Farmaceuti | USE OF 2-AMINOTETRALINE-6,7-SUBSTITUTED FOR THE PREPARATION OF PHARMACEUTICAL COMPOSITIONS SUITABLE FOR THE TREATMENT OF SHOCK, AND OF |
IT1294931B1 (en) | 1997-09-22 | 1999-04-23 | Sigma Tau Ind Farmaceuti | DERIVATIVES OF 2-AMINOTETHRALIN PROCEDURE FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, ACTIVE IN THE |
SE9801726D0 (en) | 1998-05-15 | 1998-05-15 | Astra Ab | New process |
CA2338328A1 (en) | 1998-07-21 | 2000-02-03 | Thomas Jefferson University | Small molecule inhibitors of bcl-2 proteins |
DE69918264T2 (en) | 1999-04-19 | 2004-10-21 | Gen Electric | Bis-silyl tertiary amines |
US20010039343A1 (en) | 2000-01-28 | 2001-11-08 | Mulvihill Mark Joseph | Process to intermediates for biologically active compounds |
DZ3415A1 (en) * | 2000-08-31 | 2002-03-07 | Chiron Corp | GUANIDINOBENZAMIDES AS MC4-R AGONISTS. |
US20020094316A1 (en) | 2001-01-09 | 2002-07-18 | Shuang Liu | Polypodal chelants for metallopharmaceuticals |
-
2003
- 2003-10-08 US US10/681,578 patent/US7125904B2/en active Active
- 2003-10-10 JP JP2004542666A patent/JP4620464B2/en not_active Expired - Fee Related
- 2003-10-10 WO PCT/GB2003/004430 patent/WO2004033447A1/en active Application Filing
- 2003-10-10 RU RU2005114021/04A patent/RU2332416C2/en active
- 2003-10-10 EP EP07076122A patent/EP1914233B8/en not_active Expired - Lifetime
- 2003-10-10 KR KR1020057006221A patent/KR101155159B1/en active IP Right Grant
- 2003-10-10 CA CA2501819A patent/CA2501819C/en not_active Expired - Lifetime
- 2003-10-10 BR BRPI0315143A patent/BRPI0315143B8/en not_active IP Right Cessation
- 2003-10-10 PL PL376224A patent/PL218537B1/en unknown
- 2003-10-10 EP EP07076124A patent/EP1911757B8/en not_active Expired - Lifetime
- 2003-10-10 EP EP07076125A patent/EP1908760B1/en not_active Expired - Lifetime
- 2003-10-10 EP EP03256420A patent/EP1408038B1/en not_active Expired - Lifetime
- 2003-10-10 AU AU2003271945A patent/AU2003271945B2/en not_active Ceased
- 2003-10-10 PT PT103029A patent/PT103029B/en active IP Right Grant
- 2003-10-10 MX MXPA05003847A patent/MXPA05003847A/en active IP Right Grant
- 2003-10-10 EP EP07076123A patent/EP1908759B1/en not_active Expired - Lifetime
-
2006
- 2006-09-20 US US11/533,462 patent/US7259271B2/en not_active Expired - Lifetime
-
2007
- 2007-02-15 GB GB0702982A patent/GB2432159B/en not_active Expired - Fee Related
- 2007-02-15 GB GB0702981A patent/GB2432158B/en not_active Expired - Fee Related
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1995029165A2 (en) * | 1994-04-26 | 1995-11-02 | Syntex (U.S.A.) Inc. | Benzocycloalkylaz0lethione derivatives as dopamin beta-hydroxylase inhibitors |
Cited By (48)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007081232A1 (en) * | 2006-01-13 | 2007-07-19 | Bial- Portela & Ca, S.A. | Drug combinations |
JP2009523720A (en) * | 2006-01-13 | 2009-06-25 | バイアル−ポルテラ アンド シーエー,エス.エー. | Drug combination |
WO2007139413A2 (en) | 2006-05-31 | 2007-12-06 | Bial - Portela & C.A., S.A. | Polymorphs of (r) -5- (2-aminoethyl) -1- (6, 8-difluorochroman-3-yl) -1,3- dihydroimidazole-thione hydrochloride |
WO2007139413A3 (en) * | 2006-05-31 | 2008-04-03 | Portela & Ca Sa | Polymorphs of (r) -5- (2-aminoethyl) -1- (6, 8-difluorochroman-3-yl) -1,3- dihydroimidazole-thione hydrochloride |
US8546571B2 (en) | 2006-12-12 | 2013-10-01 | BIAL—Portela & C.A., S.A. | Catalytic hydrogenation of ene-carbamates |
WO2008085074A2 (en) * | 2007-01-12 | 2008-07-17 | Bial-Portela & Ca., S.A. | 1, 3-dihydroimidazoles for treating cardiovascular disorders |
WO2008085074A3 (en) * | 2007-01-12 | 2008-12-11 | Portela & Ca Sa | 1, 3-dihydroimidazoles for treating cardiovascular disorders |
WO2008094054A3 (en) * | 2007-02-01 | 2008-09-18 | Portela & Ca Sa | 6, 8-dichlorchroman-3-yl-l, 3-dihydroimidazole-2-thione derivatives and their use for the treatment of cardiovascular disorders |
WO2008094056A1 (en) * | 2007-02-01 | 2008-08-07 | Bial - Portela & Ca, S.A. | Process for the preparation of (r) -5- (2-aminoethyl) -1- (6, 8 -di fluorochroman- s -yl ) -1, 3-dihydroimidazole-2-thione |
WO2008094055A1 (en) * | 2007-02-01 | 2008-08-07 | Bial-Portela & Ca, S.A. | Process for the preparation of (r) -5- (2-aminoethyl) -1- (6, 8-difluorochroman-3-yl) -1, 3-dihydroimidazole-2-thione |
US20100121073A1 (en) * | 2007-02-01 | 2010-05-13 | Bial - Portela & Ca S.A. | Process for the Preparation of (R)-5-(2-Aminoethyl)-1-(6,8-Difluorochroman-3-YL)-1,3-Dihydroimidazole-2-Thione |
US8158666B2 (en) | 2007-02-01 | 2012-04-17 | Bial-Portela & C.A., S.A. | Process for the preparation of (R)-5-(2-aminoethyl)-1-(6,8-difluorochroman-3-YL)-1,3-dihydroimidazole-2-thione |
JP2010517999A (en) * | 2007-02-01 | 2010-05-27 | バイアル−ポルテラ アンド シーエー,エス.エー. | Process for producing (R) -5- (2-aminoethyl) -1- (6,8-difluorochroman-3-yl) -1,3-dihydroimidazol-2-thione |
WO2008136695A1 (en) * | 2007-05-08 | 2008-11-13 | Portela & Ca, S.A. | 1, 3-dihydroimidazole- 2 -thione derivatives as inhibitors of dopamine-beta-hydroxylase |
KR20100017546A (en) * | 2007-05-08 | 2010-02-16 | 바이알 - 포르텔라 앤드 씨에이 에스에이 | 1,3-dihydroimidazole-2-thione derivatives as inhibitors of dopamine-beta-hydroxylase |
KR101598482B1 (en) * | 2007-05-08 | 2016-02-29 | 바이알 - 포르텔라 앤드 씨에이 에스에이 | -- 13--2- 13-dihydroimidazole-2-thione derivatives as inhibitors of dopamine-beta-hydroxylase |
US9630951B2 (en) | 2007-05-08 | 2017-04-25 | Bial-Portela & Ca, S.A. | 1,3-dihydroimidazole-2-thione derivatives as inhibitors of dopamine-beta-hydroxylase |
US8481582B2 (en) | 2007-05-08 | 2013-07-09 | Bial-Portela & Ca, S.A. | 1,3-dihydroimidazole-2-thione derivatives as inhibitors of dopamine-beta-hydroxylase |
AU2008246443B2 (en) * | 2007-05-08 | 2013-07-11 | Bial - Portela & Ca, S.A. | 1, 3-dihydroimidazole- 2 -thione derivatives as inhibitors of dopamine-beta-hydroxylase |
WO2009072915A1 (en) | 2007-12-05 | 2009-06-11 | Bial - Portela & Ca., S.A. | New salts and crystal forms |
WO2009113891A1 (en) * | 2008-03-13 | 2009-09-17 | Bial - Portela & Ca., S.A. | Catalytic process for asymmetric hydrogenation |
US8957222B2 (en) | 2008-03-19 | 2015-02-17 | Bial-Portela & Ca, S.A. | Process for preparing intermediates of peripherally-selective inhibitors of dopamine-β-hydroxylase involving catalytic asymmetric hydrogenation |
US8710239B2 (en) | 2008-05-06 | 2014-04-29 | BIAL—Portela & C.A., S.A. | Process for preparing synthetic intermediates of peripherally-selective inhibitors of dopamine-β-hydroxylase involving catalytic asymmetric hydrogenation |
WO2009136803A3 (en) * | 2008-05-06 | 2010-07-22 | Bial - Portela & Ca., S.A. | Catalytic process for asymmetric hydrogenation |
US10821186B2 (en) | 2008-11-10 | 2020-11-03 | Arbutus Biopharma Corporation | Lipids and compositions for the delivery of therapeutics |
WO2013002660A2 (en) | 2011-06-29 | 2013-01-03 | BIAL - PORTELA & Cª, S.A. | Process |
US9346751B2 (en) | 2011-06-29 | 2016-05-24 | Bial-Portela & Ca, S.A. | Process for preparing 1, 3-Dihydroimidazole-2-Thione Derivatives |
US10059696B2 (en) | 2011-06-29 | 2018-08-28 | Bial-Portela & Ca, S.A. | Process for preparing 1,3-dihydroimidazole-2-thione derivatives |
KR20150084022A (en) * | 2012-11-14 | 2015-07-21 | 바이알 - 포르텔라 앤드 씨에이 에스에이 | 1,3-dihydroimidazole-2-thione derivatives for use in the treatment of pulmonary arterial hypertension and lung injury |
KR102259938B1 (en) | 2012-11-14 | 2021-06-03 | 바이알 - 포르텔라 앤드 씨에이 에스에이 | 1,3-dihydroimidazole-2-thione derivatives for use in the treatment of pulmonary arterial hypertension and lung injury |
US9604970B2 (en) | 2012-11-14 | 2017-03-28 | Bial-Portela & Ca, S.A. | 1,3-dihydroimidazole-2-thione derivatives for use in the treatment of pulmonary arterial hypertension and lung injury |
WO2014077715A1 (en) * | 2012-11-14 | 2014-05-22 | BIAL - PORTELA & Cª, S.A. | 1,3-dihydroimidazole-2-thione derivatives for use in the treatment of pulmonary arterial hypertension and lung injury |
US10308640B2 (en) | 2012-11-14 | 2019-06-04 | Bial-Portela & Ca, S.A. | 1,3-dihydroimidazole-2-thione derivatives for use in the treatment of pulmonary arterial hypertension and lung injury |
US20190241545A1 (en) * | 2012-11-14 | 2019-08-08 | Bial - Portela & Ca S.A. | 1,3-Dihydroimidazole-2-Thione Derivatives for Use in the Treatment of Pulmonary Arterial Hypertension and Lung Injury |
US10329268B2 (en) | 2013-09-13 | 2019-06-25 | Bial-Portela & Ca, S.A. | Processes for preparing medicaments for the treatment of cardiovascular diseases and intermediates for use therein |
EP3808737A1 (en) | 2013-09-13 | 2021-04-21 | BIAL - Portela & Ca., S.A. | Processes for preparing medicaments for the treatment of cardiovascular diseases and intermediates for use therein |
CN109715633A (en) * | 2016-09-23 | 2019-05-03 | 巴尔-波特拉及康邦亚股份有限公司 | Dopamine-B-hydroxylase inhibitors |
WO2018056855A1 (en) * | 2016-09-23 | 2018-03-29 | BIAL - PORTELA & Cª, S.A. | Dopamine-b-hydroxylase inhibitors |
US10975083B2 (en) | 2016-09-23 | 2021-04-13 | Bial—Portela & Ca, S.A. | Blood-brain barrier-penetrant dopamine-β-hydroxylase inhibitors |
CN109715155A (en) * | 2016-09-23 | 2019-05-03 | 巴尔-波特拉及康邦亚股份有限公司 | Blood-brain barrier-penetrating agent dopamine-B-hydroxylase inhibitors |
WO2018056854A1 (en) | 2016-09-23 | 2018-03-29 | BIAL - PORTELA & Cª, S.A. | Blood-brain barrier-penetrant dopamine-b-hydroxylase inhibitors |
US11034695B2 (en) | 2016-09-23 | 2021-06-15 | BIAL—Portela & Cᵃ, S.A. | Dopamine-β-hydroxylase inhibitors |
TWI746644B (en) * | 2016-09-23 | 2021-11-21 | 葡萄牙商比亞爾 波特拉公司 | DOPAMINE-β-HYDROXYLASE INHIBITORS |
AU2017330175B2 (en) * | 2016-09-23 | 2022-02-17 | BIAL - PORTELA & Cª, S.A. | Dopamine-β-hydroxylase inhibitors |
WO2019112457A1 (en) | 2017-12-04 | 2019-06-13 | BIAL - PORTELA & Cª, S.A. | Dopamine-β-hydroxylase inhibitors |
US11434242B2 (en) | 2017-12-04 | 2022-09-06 | Bial—Portela & Ca, S.A. | Dopamine-b-hydroxylase inhibitors |
WO2020005087A1 (en) | 2018-06-25 | 2020-01-02 | Bial - Portela & Ca, S.A. | FORMULATIONS COMPRISING DOPAMINE-β-HYDROXYLASE INHIBITORS AND METHODS FOR THEIR PREPARATION |
WO2020246903A1 (en) | 2019-06-05 | 2020-12-10 | BIAL - PORTELA & Cª, S.A. | Dopamine-β-hydroxylase inhibitors |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US7259271B2 (en) | Peripherally-selective inhibitors of dopamine-β-hydroxylase and method of their preparation | |
CA2227235C (en) | Novel galanthamine derivatives, preparation method therefor, use thereof as drugs, and pharmaceutical compositions containing such derivatives | |
WO2008094054A2 (en) | 6, 8-dichlorchroman-3-yl-l, 3-dihydroimidazole-2-thione derivatives and their use for the treatment of cardiovascular disorders | |
GB2393958A (en) | Peripherally-selective imidazole inhibitors of dopamine-beta-hydroxylase | |
US20100286219A1 (en) | 1, 3-Dihydroimidazoles for Treating Cardiovascular Disorders |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2501819 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: PA/a/2005/003847 Country of ref document: MX Ref document number: 376224 Country of ref document: PL Ref document number: 2004542666 Country of ref document: JP Ref document number: 1020057006221 Country of ref document: KR Ref document number: 2003271945 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1599/DELNP/2005 Country of ref document: IN |
|
ENP | Entry into the national phase |
Ref document number: 2005114021 Country of ref document: RU Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 20038A59426 Country of ref document: CN |
|
WWP | Wipo information: published in national office |
Ref document number: 1020057006221 Country of ref document: KR |
|
122 | Ep: pct application non-entry in european phase |